Cytokinetics (KK3A) Ownership - Who Owns Cytokinetics?
Cytokinetics (KK3A) Ownership Overview
- 0.63% Insiders
- 36.09% Mutual Funds
- 1.11% Other Institutional Investors
- 25.94% ETFs
- 36.23% Public Companies and Individual Investors
The ownership structure of Cytokinetics (DE:KK3A) stock is a mix of institutional, retail, and individual investors. Approximately 63.14% of the company’s stock is owned by Institutional Investors, 0.63% is owned by Insiders, and 36.23% is owned by Public Companies and Individual Investors.
The ownership structure of Cytokinetics (DE:KK3A) stock is a mix of institutional, retail, and individual investors. Approximately 63.14% of the company’s stock is owned by Institutional Investors, 0.63% is owned by Insiders, and 36.23% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Oct 19, 2026 | Fady Ibraham Malik | $224,035 | |
| Oct 12, 2026 | Robert Blum | $471,600 | |
| Sep 27, 2026 | Robert Blum | $490,950 | |
| Sep 21, 2026 | Fady Ibraham Malik | $239,015 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Carlson Capital Lp | €355,824 | |
| Dec 31, 2025 | Royce & Associates Llc | €9,176,828 | |
| Dec 31, 2025 | Gilder Gagnon Howe & Co Llc. | €24,515,002 | |
| Dec 31, 2025 | Fisher Asset Management Llc | €52,286,112 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard | 12,743,871 | Institution | 9.17% | 808,547,639 |
| Ishares | 12,563,886 | Institution | 9.04% | 797,128,311 |
| Vanguard Index Funds | 10,779,793 | Institution | 7.75% | 683,934,747 |
| T. Rowe Price Capital Appreciation Fund, Inc. | 6,285,983 | Institution | 4.52% | 398,820,477 |
| Spdr | 5,358,182 | Institution | 3.85% | 339,955,215 |
| Vanguard Specialized Funds | 3,341,262 | Institution | 2.40% | 211,989,709 |
| Smallcap World Fund Inc | 2,997,051 | Institution | 2.16% | 190,150,898 |
| Fidelity Securities Fund | 2,635,153 | Institution | 1.90% | 167,189,917 |
| T. Rowe Price Mid-cap Growth Fund, Inc. | 1,972,209 | Institution | 1.42% | 125,128,772 |
| Fidelity Salem Street Trust | 1,642,962 | Institution | 1.18% | 104,239,367 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 10,779,793 | Institution | 7.75% | 683,934,747 |
| T. Rowe Price Capital Appreciation Fund, Inc. | 6,285,983 | Institution | 4.52% | 398,820,477 |
| Vanguard Specialized Funds | 3,341,262 | Institution | 2.40% | 211,989,709 |
| Smallcap World Fund Inc | 2,997,051 | Institution | 2.16% | 190,150,898 |
| Fidelity Securities Fund | 2,635,153 | Institution | 1.90% | 167,189,917 |
| T. Rowe Price Mid-cap Growth Fund, Inc. | 1,972,209 | Institution | 1.42% | 125,128,772 |
| Fidelity Salem Street Trust | 1,642,962 | Institution | 1.18% | 104,239,367 |
| Fidelity Concord Street Trust | 1,371,479 | Institution | 0.99% | 87,014,857 |
| T. Rowe Price Small-cap Value Fund, Inc. | 1,132,329 | Institution | 0.81% | 71,841,746 |
| Vanguard Scottsdale Funds | 895,095 | Institution | 0.64% | 56,790,197 |
FAQ
Who Owns Cytokinetics (DE:KK3A)?
According to the latest TipRanks data, approximately 63.14% of the company's stock is held by institutional investors, 0.63% is held by insiders, and 36.23% is held by public companies and individual investors.
What percentage of Cytokinetics (DE:KK3A) stock is held by institutional investors?
According to the latest TipRanks data, approximately 63.14% of Cytokinetics (DE:KK3A) stock is held by institutional investors: 36.09% by mutual funds, 25.94% by ETFs and 1.11% by other institutional investors.
What percentage of Cytokinetics (DE:KK3A) stock is held by retail investors?
According to the latest TipRanks data, approximately 36.23% of Cytokinetics (DE:KK3A) stock is held by public companies and individual investors.
Who owns the most shares of Cytokinetics (DE:KK3A)?
Vanguard owns the most shares of Cytokinetics (DE:KK3A).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.